Henlius to Establish Saudi Arabia JVs to Distribute Drugs to Middle East

MT Newswires Live11-08

Shanghai Henlius Biotech (HKG:2696) will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according to a Thursday press release by Henlius.

The Saudi Arabian company, owned by the Fakeeh family, together with Henlius, will market adalimumab and bevacizumab products, in the Middle East, North Africa, and Türkiye, according to the Hong Kong-listed company.

Adalimumab is indicated for rheumatoid arthritis and inflamed joints, while bevacizumab is a cancer treatment.

The two companies will also jointly develop pembrolizumab, another antibody for melanoma, lung cancer, Hodgkin lymphoma, and cancers of the stomach, cervix, head and neck

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2481914943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-08 16:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2481914943","market":"sg","top_or_hot":-1,"title":"Henlius to Establish Saudi Arabia JVs to Distribute Drugs to Middle East","media":"MT Newswires Live","content":"<html><body><p> Shanghai Henlius Biotech (HKG:2696) will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according to a Thursday press release by Henlius.</p><p>The Saudi Arabian company, owned by the Fakeeh family, together with Henlius, will market adalimumab and bevacizumab products, in the Middle East, North Africa, and Türkiye, according to the Hong Kong-listed company.</p><p>Adalimumab is indicated for rheumatoid arthritis and inflamed joints, while bevacizumab is a cancer treatment.</p><p>The two companies will also jointly develop pembrolizumab, another antibody for melanoma, lung cancer, Hodgkin lymphoma, and cancers of the stomach, cervix, head and neck</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Henlius to Establish Saudi Arabia JVs to Distribute Drugs to Middle East</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHenlius to Establish Saudi Arabia JVs to Distribute Drugs to Middle East\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-08 16:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shanghai Henlius Biotech (HKG:2696) will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02696","symbol_name":"复宏汉霖","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2481914943","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2481914943","pubTimestamp":1731053107,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shanghai Henlius Biotech  will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according to a Thursday press release by Henlius.The Saudi Arabian company, owned by the Fakeeh family, together with Henlius, will market adalimumab and bevacizumab products, in the Middle East, North Africa, and Türkiye, according to the Hong Kong-listed company.Adalimumab is indicated for rheumatoid arthritis and inflamed joints, while bevacizumab is a cancer treatment.The two companies will also jointly develop pembrolizumab, another antibody for melanoma, lung cancer, Hodgkin lymphoma, and cancers of the stomach, cervix, head and neck","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02696":"复宏汉霖","BK1161":"生物科技"},"translate_title":"复宏汉霖将在沙特阿拉伯建立合资企业向中东分销药品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"Shanghai Henlius Biotech (HKG:2696) will set up two joint ventures with Saudi Arabia-based Al Tiryaq Al-Khalawi Medical or SVAX to produce and distribute pharmaceuticals in the Middle East, according to a Thursday press release by Henlius.The Saudi Arabian company, owned by the Fakeeh family, together with Henlius, will market adalimumab and bevacizumab products, in the Middle East, North Africa, and Türkiye, according to the Hong Kong-listed company.Adalimumab is indicated for rheumatoid arthritis and inflamed joints, while bevacizumab is a cancer treatment.The two companies will also jointly develop pembrolizumab, another antibody for melanoma, lung cancer, Hodgkin lymphoma, and cancers of the stomach, cervix, head and neck","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2481914943"}